THE INDIAN PHARMACIST Official Circular Pharmacy LogoTHE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
Antimicrobial Stewardship & Infectious Diseases ARTICLE ID: KH-23 ⏱️ 11 min read 📅 Updated: 2026-11-10

Safe Use of Antibiotics and Preventing Antimicrobial Resistance

🎯 Key Takeaways Summary

  • Never take or dispense antibiotics for viral colds, flu, dengue, or non-bloody viral diarrhoea.
  • Prioritise WHO 'Access' antibiotics (e.g., amoxicillin, nitrofurantoin) over 'Watch' antibiotics (e.g., azithromycin, cefixime, ciprofloxacin) for routine community infections.
  • Obtain blood/urine/sputum cultures BEFORE administering the first dose of empiric IV antibiotics in hospitalised patients, then de-escalate at 48–72 hours.
  • Protect 'Reserve' antibiotics (polymyxin B, colistin, ceftazidime-avibactam, bedaquiline) through strict hospital stewardship sign-off.

1. Foundational Clinical & Scientific Overview

Antimicrobial Resistance (AMR) occurs when bacteria, viruses, fungi, or parasites evolve mechanisms that render antimicrobial medicines ineffective. In India, where Gram-negative resistance (ESBL-producing Escherichia coli and KPC/NDM/OXA-48 carbapenem-resistant Klebsiella pneumoniae and Acinetobacter baumannii) poses a severe clinical challenge, rational antibiotic use guided by the WHO AWaRe (Access, Watch, Reserve) classification and ICMR Antimicrobial Stewardship Guidelines is essential.

2. Core Mechanisms, Classification & Practical Framework

Antibiotics selectively target bacterial structures (peptidoglycan cell wall synthesis, 30S/50S ribosomal subunits, bacterial DNA gyrase/topoisomerase IV, RNA polymerase, or folate synthesis) and have ZERO activity against viral infections such as the common cold, influenza, dengue, chikungunya, or most cases of acute watery diarrhoea and acute viral pharyngitis.

Structured Classification & Practical Examples

  • ACCESS Group Antibiotics (First-Line Narrow-Spectrum): Amoxicillin, Amoxicillin-Clavulanate, Cefalexin, Doxycycline, Nitrofurantoin, Metronidazole, and Cotrimoxazole — lower resistance potential, recommended as empiric first-line therapy for common community infections.
  • WATCH Group Antibiotics (Broad-Spectrum — High Resistance Selection): Azithromycin, Ciprofloxacin, Levofloxacin, Cefixime, Ceftriaxone, Cefoperazone-Sulbactam, Piperacillin-Tazobactam, and Meropenem — Schedule H1 controlled; must not be used for viral fevers or uncomplicated upper respiratory infections.
  • RESERVE Group Antibiotics (Last-Resort Salvage Only): Colistin, Polymyxin B, Tigecycline, Linezolid, Tedizolid, Ceftazidime-Avibactam, Meropenem-Vaborbactam, Cefiderocol, Daptomycin, and Oritavancin — restricted strictly to culture-confirmed multidrug-resistant (MDR/XDR) hospital infections.
  • PK/PD Dosing Optimization: Time-dependent killers (Beta-lactams: fT > MIC) benefit from frequent dosing or extended 3-hour IV infusions, whereas concentration-dependent killers (Aminoglycosides, Fluoroquinolones: Cmax/MIC and AUC/MIC) require optimized peak dosing.

3. Advanced Clinical Pharmacy, Dosing & Indian Regulatory Application

Molecular Resistance Mechanisms in Indian Hospitals: Indian ICU Gram-negative isolates frequently co-harbour New Delhi Metallo-beta-lactamase (blaNDM-1, Ambler Class B zinc-dependent enzyme that hydrolyses all penicillins, cephalosporins, and carbapenems except Aztreonam) alongside OXA-48 or CTX-M-15 ESBLs (which hydrolyse Aztreonam). Consequently, Ceftazidime-Avibactam alone fails against pure NDM producers, requiring synergistic co-administration of Ceftazidime-Avibactam + Aztreonam (where Avibactam protects Aztreonam from ESBL/OXA-48 while Aztreonam evades NDM hydrolysis) or Cefiderocol.

4. Common Misunderstandings & Pharmacist Safety Safeguards

⚠️ Clinical Pitfall & Safety Note: Common Misunderstanding: Stopping an antibiotic course after 2 days as soon as fever subsides, or taking leftover Azithromycin/Cefixime for a viral sore throat. Sub-therapeutic exposure kills susceptible bacteria while selecting resistant sub-clones.

5. Explanatory Visual Pharmacology Diagram (svg-v339-09-antimicrobial-mechanisms-bacterial-cell)

ANTIBACTERIAL MECHANISMS OF ACTION: CELL WALL, 30S/50S RIBOSOME, DNA & FOLATE 1. Cell-Wall Synthesis (Bactericidal) • Beta-Lactams (Penicillins, Cephalosporins, Meropenem): Inhibit PBPs (Transpeptidase) • Vancomycin: Binds D-Ala-D-Ala peptide • Fosfomycin: Inhibits MurA enolpyruvyl PK/PD: Time-dependent (fT > MIC) 2. 30S Ribosomal Subunit • Aminoglycosides (Gentamicin, Amikacin): Irreversible 30S binding & mRNA misreading (Bactericidal; Cmax/MIC; Ototoxic/Nephrotoxic) • Tetracyclines (Doxycycline) & Tigecycline: Block aminoacyl-tRNA binding at 30S A-site 3. 50S Ribosomal Subunit • Macrolides (Azithromycin, Clarithromycin) & Clindamycin: Block 23S rRNA translocation • Linezolid: Blocks 70S initiation complex (MRSA/VRE) • Chloramphenicol: Inhibits peptidyl transferase Mostly bacteriostatic (Linezolid vs Staph/Strep) 4. Nucleic Acid Synthesis (DNA Gyrase & RNA Pol) • Fluoroquinolones (Ciprofloxacin, Levofloxacin, Moxifloxacin): Inhibit DNA Gyrase (Topoisomerase II) & Topoisomerase IV (Bactericidal) • Rifampicin: Inhibits bacterial DNA-dependent RNA polymerase (β-subunit) • Metronidazole: Reduced nitro group forms free radicals that strand-break DNA 5. Folate Pathway & Cell Membrane Disruptors • PABA → [Sulfamethoxazole blocks Dihydropteroate Synthase] → Dihydrofolate • Dihydrofolate → [Trimethoprim blocks DHFR] → Tetrahydrofolate (Co-trimoxazole) • Polymyxins (Colistin): Bind LPS outer membrane of MDR Gram-negative bacilli • Daptomycin: Ca2+-dependent membrane depolarisation of Gram-positive cocci (MRSA)
8.9 Antibiotic Mechanisms of Action: Cell-Wall Synthesis, Ribosomal 30S/50S Protein Synthesis, DNA Gyrase & Folate Pathway: Figure 8.9: Mechanisms of action of major antibacterial classes across bacterial cell-wall synthesis, 30S/50S ribosomal protein translation, nucleic acid replication, and folic acid biosynthesis.

6. Authoritative References & Editorial Traceability

Primary Reference Sources: ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes; WHO AWaRe Antibiotic Book; NCDC National Treatment Guidelines for Antimicrobial Use.

Official Portals: CDSCO • Indian Pharmacopoeia Commission (IPC / NFI) • ICMR • FSSAI • NCBI Bookshelf

Educational Disclaimer: Published for pharmacy education, academic learning, and professional clinical reference. Never self-medicate or alter prescribed treatment without consulting a qualified medical practitioner.

← Previous: What Are Schedule H, Schedule H1, and Sche... All 40 Articles Next: Understanding Cancer Medicines: Chemothera... →